

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

ANNOUNCEMENT

POSITIVE PROFIT ALERT

This announcement is made by AK Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the currently available preliminary assessment of the unaudited consolidated management accounts of the Company for the year ended 31 December 2024 (the “**Unaudited Management Accounts**”), the Board expects the Group to record a significant increase in net profit attributable to Shareholders by over 50% for the year ended 31 December 2024 as compared to the net profit attributable to Shareholders for the year ended 31 December 2023 (FY2023: RMB182,104,000).

The increase in net profit attributable to Shareholders for the year ended 31 December 2024 was primarily due to: (1) the continued growth in the demand for the Group’s surgical products and the increase in the revenue of the Group’s products brought by the national volume-based procurement, arising from further acceleration of import substitution driven by the national volume-based procurement policy; and (2) the relatively stable operational costs and administrative expenses through effective cost control measures executed by the Group.

As at the date of this announcement, the Company is still in the process of preparing the annual results of the Group for the year ended 31 December 2024 and is not able at this time to disclose any further details on the above factors and their impact on the Group’s net profit attributable to Shareholders. The information set out above is only based on a preliminary assessment by the Board on the information currently available to it, including the Unaudited Management Accounts, which have not been finalised and have not been independently audited by the Company’s auditors or reviewed by the audit committee of the Company. Shareholders and potential investors should refer to and review the annual results of the Group for the year ended 31 December 2024, which are expected to be published by the end of March 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, 9 February 2025

As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Dr. Wang David Guowei as non-executive Director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Dr. Gao Wei as independent non-executive Directors.